Valuation: Cogstate Limited

Market Cap 454M 317M 277M 256M 235M 445M 30.57B 3.06B 1.2B 14.97B 1.19B 1.17B 51.49B P/E 2026 *
27.2x
P/E 2027 * 20x
Enterprise Value 396M 277M 242M 224M 206M 389M 26.72B 2.67B 1.05B 13.08B 1.04B 1.02B 45B EV / Sales 2026 *
4.56x
EV / Sales 2027 * 3.73x
Free-Float
54.18%
Yield 2026 *
1.22%
Yield 2027 * 1.53%

Last Transcript: Cogstate Limited

1 day+6.42%
1 week+6.42%
Current month+5.29%
1 month+5.29%
3 months+31.44%
6 months+24.38%
Current year+24.38%
1 month 1.8
Extreme 1.8
1.99
Current year 1.26
Extreme 1.26
1.99
1 year 1
Extreme 1
2.1
3 years 0.55
Extreme 0.553
2.1
5 years 0.55
Extreme 0.553
2.1
10 years 0.14
Extreme 0.14
2.1
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 1999-12-16
Chief Executive Officer - 2005-11-30
Director of Finance/CFO - 2021-01-31
Director TitleAgeSince
Director/Board Member - 2011-02-28
Chairman 67 2009-11-02
Director/Board Member - 2017-01-19
Change 5-day change 1-year change 3-year change Capi.($)
+6.42%+6.42% - - 328M
-1.07%+0.38%+2.06%+5.66% 50.35B
-2.85%-5.58%+373.90%+572.09% 39.21B
+1.78%+3.29%+33.49%-4.80% 34.52B
+1.98%+5.15%+17.69%+61.68% 34.6B
+0.06%-0.57%+3.35%+27.42% 27.05B
-3.27%-6.27% - - 16.68B
+1.64%+1.11%+72.02%+121.18% 15.11B
+0.29%+3.64%+15.30%+17.80% 13.85B
-1.21%+2.74%+16.77%-30.96% 13.18B
Average +0.38%+0.81%+66.82%+96.26% 27.17B
Weighted average by Cap. -0.30%+0.70%+79.63%+118.91%

Financials

2026 *2027 *
Net sales 86.95M 60.81M 53.13M 49.13M 45.09M 85.37M 5.86B 586M 230M 2.87B 228M 223M 9.87B 102M 71.52M 62.49M 57.79M 53.03M 100M 6.89B 689M 271M 3.37B 269M 263M 11.61B
Net income 16.9M 11.82M 10.33M 9.55M 8.76M 16.59M 1.14B 114M 44.74M 558M 44.39M 43.42M 1.92B 22.92M 16.03M 14.01M 12.95M 11.89M 22.51M 1.55B 155M 60.69M 756M 60.21M 58.9M 2.6B
Net Debt -57.17M -39.99M -34.94M -32.31M -29.65M -56.13M -3.85B -385M -151M -1.89B -150M -147M -6.49B -72.31M -50.58M -44.19M -40.86M -37.5M -71M -4.87B -488M -191M -2.39B -190M -186M -8.21B
Logo Cogstate Limited
Cogstate Limited is a neuroscience technology company optimizing brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Its principal activities are the creation, validation, and commercialization of digital brain health assessments; and design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments. Its segments include Clinical Trials, Healthcare, and Administration. In the Clinical Trials segment, the technology and associated services are used to quantify the effect of disease and of drugs, devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical, and biotechnology companies. In the Healthcare segment, the technology and associated services are being developed as a tool for primary care physicians and/or hospitals to assess cognitive decline.
Employees
160
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.670AUD
Average target price
3.540AUD
Spread / Average Target
+32.58%

Quarterly revenue - Rate of surprise